TW202321198A - 芳基醯胺衍生物的製造方法 - Google Patents

芳基醯胺衍生物的製造方法 Download PDF

Info

Publication number
TW202321198A
TW202321198A TW111127162A TW111127162A TW202321198A TW 202321198 A TW202321198 A TW 202321198A TW 111127162 A TW111127162 A TW 111127162A TW 111127162 A TW111127162 A TW 111127162A TW 202321198 A TW202321198 A TW 202321198A
Authority
TW
Taiwan
Prior art keywords
compound
methyl
fluoro
alkyl
amino
Prior art date
Application number
TW111127162A
Other languages
English (en)
Chinese (zh)
Inventor
桑田和明
染谷英寿
Original Assignee
日商中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中外製藥股份有限公司 filed Critical 日商中外製藥股份有限公司
Publication of TW202321198A publication Critical patent/TW202321198A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00—Other general methods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111127162A 2021-07-21 2022-07-20 芳基醯胺衍生物的製造方法 TW202321198A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-120977 2021-07-21
JP2021120977 2021-07-21

Publications (1)

Publication Number Publication Date
TW202321198A true TW202321198A (zh) 2023-06-01

Family

ID=84980009

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111127162A TW202321198A (zh) 2021-07-21 2022-07-20 芳基醯胺衍生物的製造方法

Country Status (12)

Country Link
US (1) US20240327355A1 (enExample)
EP (1) EP4375273A4 (enExample)
JP (2) JP7268255B1 (enExample)
KR (1) KR102671612B1 (enExample)
CN (1) CN117677607A (enExample)
AR (1) AR126517A1 (enExample)
AU (1) AU2022312992A1 (enExample)
CA (1) CA3226827A1 (enExample)
IL (1) IL310123A (enExample)
MX (1) MX2024000908A (enExample)
TW (1) TW202321198A (enExample)
WO (1) WO2023003014A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025007811A1 (zh) * 2023-07-06 2025-01-09 成都华健未来科技有限公司 一类芳香酰胺类衍生物及其用途
WO2025146040A1 (zh) * 2024-01-01 2025-07-10 华健未来（成都）科技股份有限公司 芳香酰肼类衍生物及其医药用途
CN118604164B (zh) * 2024-05-15 2025-06-06 石家庄四药有限公司 一种非奈利酮中间体中杂质的检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200520745A (en) * 2003-09-19 2005-07-01 Chugai Pharmaceutical Co Ltd Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
JP2016034900A (ja) * 2012-11-26 2016-03-17 中外製薬株式会社 ５−置換−２−フェニルアミノ−ベンズアミド類の製造方法
AR121078A1 (es) * 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
JPWO2022018875A1 (enExample) * 2020-07-22 2022-01-27
BR112023000883A2 (pt) * 2020-07-22 2023-02-07 Chugai Pharmaceutical Co Ltd Composição contendo derivado de arilamida

Also Published As

Publication number Publication date
IL310123A (en) 2024-03-01
AU2022312992A1 (en) 2024-02-29
JP2023084138A (ja) 2023-06-16
US20240327355A1 (en) 2024-10-03
CN117677607A (zh) 2024-03-08
JPWO2023003014A1 (enExample) 2023-01-26
MX2024000908A (es) 2024-02-07
KR20230152797A (ko) 2023-11-03
KR102671612B1 (ko) 2024-05-31
CA3226827A1 (en) 2023-01-26
AR126517A1 (es) 2023-10-18
EP4375273A1 (en) 2024-05-29
WO2023003014A1 (ja) 2023-01-26
EP4375273A4 (en) 2025-05-21
JP7268255B1 (ja) 2023-05-02

Similar Documents

Publication Publication Date Title
TWI788763B (zh) 具有抗腫瘤活性之芳醯胺衍生物
KR102566299B1 (ko) 아릴 아마이드 유도체를 포함하는 조성물
KR102550455B1 (ko) 아릴 아마이드 유도체를 포함하는 세포 증식성 질환의 치료 또는 예방용 의약 조성물
TW202321198A (zh) 芳基醯胺衍生物的製造方法
CN103068384B (zh) 表现出抗癌和抗增生活性的环丙基二甲酰胺以及类似物
WO2023103523A1 (zh) 取代的双环杂芳基化合物作为kras g12d抑制剂
WO2021008491A1 (zh) 一种阻断pd-1/pd-l1相互作用的联苯基衍生物及其制备方法和应用
KR102904379B1 (ko) 항종양 활성을 갖는 아릴 아마이드 유도체
TWI904197B (zh) 含有芳醯胺衍生物的組合物
HK40084009B (zh) 包含芳基酰胺衍生物的组合物
HK40073328B (zh) 具有抗肿瘤活性的芳基醯胺衍生物
HK40073328A (en) Arylamide derivative having antitumor activity
EA050002B1 (ru) Способ получения производного ариламида
WO2025209520A1 (zh) 一种化合物、包含其的药物组合物及其用途
EA047579B1 (ru) Производное ариламида, обладающее противоопухолевой активностью